{"id":"W4388592087","doi":"10.1161/circep.123.012567","title":"Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)","year":2023,"lang":"en","type":"article","venue":"Circulation Arrhythmia and Electrophysiology","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vertex Pharmaceuticals (Canada); Centre Hospitalier Universitaire de Sherbrooke; Montreal Heart Institute; Public Health Ontario","funders":"Boston Scientific Corporation; American Heart Association; Sanofi; GlaxoSmithKline; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb","keywords":"Medicine; Placebo; Adverse effect; Atrial fibrillation; Randomized controlled trial; Heart rate; Anesthesia; Nasal administration; Cardiology; Internal medicine; Blood pressure","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003630787,0.001739078,0.002892351,0.000338725,0.0005092007,0.001152467,0.0008848459,0.001704798,0.007005786],"category_scores_gemma":[0.002892911,0.0009659468,0.001479143,0.0003768311,0.00110123,0.0009914293,0.0003519866,0.002577686,0.001109257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008020619,"about_ca_system_score_gemma":0.00175382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001230638,"about_ca_topic_score_gemma":0.003121821,"domain_scores_codex":[0.9988126,0.0006966424,0.00007638029,0.0001929145,0.00009677443,0.0001247443],"domain_scores_gemma":[0.9985795,0.0003764775,0.0003730353,0.0001105837,0.0001713829,0.0003889792],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9765276,0.009450261,0.0006693089,0.0005777708,0.001000184,0.00003527218,0.00005662162,0.0001412736,0.00340408,0.00007588242,0.0008743619,0.007187436],"study_design_scores_gemma":[0.971296,0.02677586,0.001167222,0.00001282864,0.0001969794,0.00001509791,0.000008432821,0.0001189653,0.0001387707,0.00002432655,0.0002403998,0.000005225871],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9740925,0.005926775,0.001271858,0.001106331,0.0009486299,0.0119377,0.002116305,0.0001931175,0.002406813],"genre_scores_gemma":[0.9727376,0.003204121,0.003666822,0.001970774,0.0008237745,0.01241058,0.001778186,0.00004234226,0.003365797],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007005786,"threshold_uncertainty_score":0.02343667,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01256061098839657,"score_gpt":0.2813638615924962,"score_spread":0.2688032506040996,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}